INTRODUCTION
============

The number of nephrons an individual has is determined before birth, and more than half of these develop in the last three months of pregnancy, up until 36 weeks [@b1-cln_73p1],[@b2-cln_73p1]. Growth restriction is a condition in which a fetus fails to grow to its genetically determined potential *in utero* [@b3-cln_73p1], and it is related to a reduction of more than one-third of the nephron population, which is not rectified after birth [@b4-cln_73p1],[@b5-cln_73p1].

A reduced nephron number is critical in the progression toward chronic renal failure, and the remaining nephrons exhibit increased glomerular filtration, hyperperfusion, compensatory hypertrophy, microalbuminuria, arterial hypertension, glomerulosclerosis, overt proteinuria, and progressive fibrosis [@b6-cln_73p1],[@b7-cln_73p1]. Most studies have focused on fetal exposure to glucocorticoids in stressful situations as a plausible mechanism for reductions in the number of nephrons [@b8-cln_73p1]. This additional intrauterine exposure to glucocorticoids is critical in the determination of kidney diseases and hypertension; it is a factor in growth inhibition [@b9-cln_73p1] and a frequent source of physiological and structural alterations associated with blood pressure adjustments, such as a reduction in nephron number [@b10-cln_73p1], activation of the renin angiotensin system [@b11-cln_73p1],[@b12-cln_73p1] and changes in the hypothalamic-pituitary-adrenal axis [@b13-cln_73p1]. However, although some studies show an influence of low birth weight (LBW) on kidney function later in life, no *consensus* is available regarding the factors that increase the risk, if any exist. Low birth weight may increase the probability of developing decreased renal function in adulthood. The investigations to date have been heterogeneous with respect to age, associated diseases, population, and definitions of outcomes; few studies have tried to synthesize all available data, but the populations evaluated were heterogeneous and were not restricted to adulthood because children and individuals with a history of extreme prematurity were also considered [@b14-cln_73p1]-[@b16-cln_73p1]. Therefore, information must be collected to investigate the influence of intrauterine growth restriction (IUGR) on the development of kidney disease in adulthood.

Therefore, our objective was to evaluate the current literature on the influence of IUGR on renal disease in adulthood.

METHODS
=======

This study was conducted following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration, Version 5.1.0 [@b17-cln_73p1].

The protocol for this review was registered at PROSPERO (CRD42017040019).

The electronic search was conducted through November of 2017 using the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL), Latin American and Caribbean Health Sciences (LILACS), Medical Literature Analysis and Retrieval System Online (MEDLINE), and EMBASE. The terms used in the Pubmed/MEDLINE search were ("Kidney Diseases" \[Mesh\]) AND "Fetal Growth Retardation" \[Mesh\] with no filters for species, sex or languages. The same terms were applied in EMBASE and CENTRAL, but with their extended trees. In LILACS, the search strategy was ("Nefropatias" OR "Kidney Diseases" OR "Enfermedades Renales") AND ("Retardo do Crescimento Fetal" OR "Fetal Growth Retardation" OR "Retardo del Crecimiento Fetal"). Initially, no filters were applied for the study design, date, or language. The authors also conducted manual searches in the included studies and reviewed the references available on the subject to identify other potentially eligible articles.

The inclusion criteria were as follows: studies evaluating low birth weight (different classifications but with possible correspondences) and kidney function in adulthood. The evaluation of kidney function could include the glomerular filtration rate, albumin-creatinine ratio, presence of microalbuminuria, or end-stage renal disease. Subjects had to be over 18 years old, and the control group was limited to subjects with a birth weight up to the 90^th^ percentile when the article provided these data. The search included publications in English, Portuguese, French, and Spanish.

The exclusion criteria were as follows: studies involving kidney function evaluation in children, animals, or a group with a specific disease (e.g., IgA nephropathy, congenital abnormalities, minimal change nephropathy, and diabetic nephropathy); studies analyzing only kidney volume; and reviews. Furthermore, we excluded studies involving very premature births (\<32 weeks), birth weights less than 1500 grams, and birth weight analyzed in quartiles; studies with missing data; and studies with different outcomes, such as the rate of low-normal creatinine clearance.

Two reviewers (JCS and MAC) independently read the titles and abstracts of the papers retrieved using the pre-defined search strategy and applied the inclusion criteria. Then, the remaining articles or the articles that did not have abstracts were obtained in full and read again, with the same eligibility criteria applied. Any selection conflicts were solved by *consensus* after discussion. Any other uncertainties were resolved by email contact with the original authors.

Then, data were extracted from the selected studies, including information on the author, date of publication, study design, number and characteristics of the participants, age, predictors, outcomes, and definitions of low birth weight, small for gestational age, IUGR, end-stage renal disease, and microalbuminuria, if applicable.

The data were analyzed using Review Manager (RevMan) 5.3. Using the Mantel-Haenszel statistical test, we compared dichotomous outcomes using the OR with the 95% CI. For continuous data, we used both the average difference (MD) and 95% CI and the statistical test of the inverse of the variance.

The heterogeneity of the data extracted from the included studies was assessed using the chi-square test and the I^2^ statistic. A difference was statistically significant if the chi-square result was *p*\<0.10 and/or I^2^\>50%. In such cases, we applied a random effects model. However, for the opposite result, we used a fixed effects model. In those cases, we assumed that each study estimated the same amount of effect (homogeneous) and that the results were different only due to chance.

The methodological quality of the cohort and case-control studies included in the meta-analysis was assessed according to the Newcastle-Ottawa Scale (NOS). Each study was judged from three broad perspectives: group selection, group comparability, and detection of the outcome or exposure of interest for case-control or cohort studies. As the evaluation of the NOS is currently in progress, we classified the studies as having a high risk of bias when they received between 0 and 4 stars, having a moderate risk of bias when they received between 5 and 7 stars, and having a low risk of bias when they received ≥8 stars. Cross-sectional studies were evaluated according the National Institutes of Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, which comprises 14 criteria.

Sensitivity analysis was performed by excluding each study individually and performing a new statistical analysis of the remaining studies. A funnel plot was not used due to the small number of studies included in each outcome.

RESULTS
=======

Search results
--------------

The search identified 901 articles, 858 of which were found through four electronic databases (MEDLINE: 224, LILACS: 3, CENTRAL: 310, EMBASE: 321) and 43 of which were found by manual search. After duplicates were removed and articles were deleted based on titles and abstracts, 129 articles remained. The full versions of these articles were evaluated. A total of 116 articles were excluded for several reasons ([Figure 1](#f1-cln_73p1){ref-type="fig"}). Finally, 13 studies were considered eligible for the systematic review and were included in the meta-analysis.

Included studies
----------------

A total of 100466 subjects who had low birth weight or were small for gestational age were compared with 914602 controls with respect to the end-stage renal disease outcome. Fan et al. [@b18-cln_73p1], Dyck et al. [@b19-cln_73p1], Lackland et al. [@b20-cln_73p1], and Al Salmi et al. [@b21-cln_73p1],[@b22-cln_73p1] defined low birth weight as below 2500 g, while Ruggajo et al. [@b23-cln_73p1] included subjects who were small for gestational age, defined as a birth weight less than the sex-specific 10^th^ percentile (2870 g for males and 2800 g for females). The control group included individuals whose birth weight was greater than the 10^th^ percentile but lower than the 90^th^ percentile (i.e., 3999 g). Neither Ruggajo et al. [@b23-cln_73p1] nor Al Salmi et al. [@b21-cln_73p1],[@b22-cln_73p1] mentioned an upper limit.

To evaluate microalbuminuria, we compared 1956 subjects who had low birth weight or were small for gestational age with 10125 controls. Only Laganovic et al. [@b24-cln_73p1] defined the predictor as small for gestational age (birth weight \<10^th^ percentile, mean: 2230 g), while Li et al. [@b25-cln_73p1] and Nelson et al. [@b26-cln_73p1] used low birth weight \<2500 g. For the outcome, Laganovic et al. [@b24-cln_73p1] defined microalbuminuria as an albumin/creatinine ratio (ACR) between 2.2 and 22 mg/mmol, while Li et al. [@b25-cln_73p1] and Nelson et al. [@b26-cln_73p1] defined it an ACR ≥30 mg/g. The upper limit of birth weight for the controls in the study by Nelson et al. (26) was 4500 g. Other studies, such as those by Gielen et al. [@b27-cln_73p1], Laganovic et al. [@b24-cln_73p1], Kistner et al. [@b28-cln_73p1], Vásárhelyi et al. [@b29-cln_73p1], and Hoy et al. [@b7-cln_73p1], did not specify a maximum.

For the quantitative outcome, the ACRs of 255 low birth weight or small for gestational age individuals were compared with those of 312 controls. Only Laganovic et al. [@b24-cln_73p1] defined the predictor as small for gestational age; Vásárhelyi et al. [@b29-cln_73p1] and Hoy et al. [@b7-cln_73p1] used low birth weight.

Finally, to analyze the glomerular filtration rate (GFR) (ml/min), 490 low birth weight or small for gestational age individuals were compared with 893 normal birth weight or adequate for gestational age individuals. For the analysis of GFR (ml/min/1.73 m^2^), 322 cases were compared with 366 controls. The formulas selected by each author to calculate the GFR were as follows: Gielen et al. [@b27-cln_73p1] used creatinine clearance, corrected for body surface area; Laganovic et al. [@b24-cln_73p1] used the Cockcroft-Gault equation; Kistner et al. [@b28-cln_73p1] used the clearance of iohexol, corrected for body surface area; and Vásárhelyi et al. [@b29-cln_73p1] used the Schwartz formula. Al Salmi et al. [@b22-cln_73p1] calculated the GFR using serum creatinine and lean body mass.

For more information on the studies included in the meta-analysis ([Table 1](#t1-cln_73p1){ref-type="table"}).

Most of the cohort and case-control studies were classified as having a moderate risk of bias according to the NOS, and the cross-sectional studies presented a mean score (which indicates the internal validity) of 52% ([Tables 2](#t2-cln_73p1){ref-type="table"} and [3](#t3-cln_73p1){ref-type="table"}).

Summary of Results
------------------

### End-Stage Renal Disease

Considering the 5 studies evaluating end-stage renal disease included in this analysis, increased risk was observed in the low birth weight group (risk ratio (RR) 1.31, 95% confidence interval (CI): 1.17, 1.47) ([Figure 2](#f2-cln_73p1){ref-type="fig"}). The sensitivity analysis, in which each study was excluded individually, did not change the result.

### Glomerular filtration rate

An increased risk of a lower GFR (ml/min) was observed in the low birth weight group (MD -7.14; 95% CI: -12.12, -2.16). However, no statistically significant difference in the GFR (ml/min/1.73 m^2^) was found between the cases and controls (MD -1.77; 95% CI: -5.08, 1.55). The sensitivity analysis also presented the same positive results with respect to the GFR (ml/min), but when the Al Salmi et al. study was excluded, the results became insignificant (MD -6.06; 95% CI: -13.14, 1.03) ([Figures 3](#f3-cln_73p1){ref-type="fig"} and [4](#f4-cln_73p1){ref-type="fig"}).

### Microalbuminuria

Considering the 3 included studies that used microalbuminuria as an outcome, an increased risk of microalbuminuria was identified in the low birth weight group (RR 1.40; 95% CI: 1.28, 1.52) ([Figure 5](#f5-cln_73p1){ref-type="fig"}). The sensitivity analysis did not change the result.

### Albumin/Creatinine ratio

A small increase in the albumin-creatinine ratio (mg/mmol) was identified in the low birth weight group compared with the controls (MD 0.46; 95% CI: 0.03, 0.90) based on the 3 relevant included studies. According to the sensitivity analysis, when either Hoy et al. [@b7-cln_73p1] or Laganovic et al. [@b24-cln_73p1] was excluded, the result was no longer statistically significant ([Figure 6](#f6-cln_73p1){ref-type="fig"}).

DISCUSSION
----------

According to our review, having a low birth weight or being small for gestational age during intrauterine development interferes with renal function in adulthood. We observed that these conditions are related to the development of microalbuminuria (RR 1.40; 95% CI: 1.28, 1.52) and end-stage renal disease (RR 1.31, 95% CI: 1.17, 1.47), a decreased glomerular filtration rate (ml/min) (MD -7.14; 95% CI: -12.12, -2.16), and a slightly increased albumin-creatinine ratio (mg/mmol) (MD 0.46; 95% CI: 0.03, 0.90).

The decrease in renal function likely occurs because the reduction in the nephron number in IUGR fetuses is not completely compensated for during the postnatal period [@b4-cln_73p1],[@b5-cln_73p1]. Therefore, the remaining nephrons are overloaded with increased glomerular filtration, compensatory hypertrophy and progressive fibrosis in a cycle of progressive loss of functioning units [@b6-cln_73p1],[@b7-cln_73p1]. Hinchliffe et al. [@b4-cln_73p1] and Giapros et al. [@b5-cln_73p1] demonstrated diminished nephron numbers and kidney lengths in this population. Indeed, the fetal response to low intrauterine oxygenation may be favorable in the short term, directing blood flow to vital organs to minimize severe hypoxia. However, vasoconstriction in peripheral organs increases risks later in life [@b30-cln_73p1]. Doro et al. [@b31-cln_73p1] recently demonstrated that in growth-restricted fetuses, renal vascular flow is impaired in the most severe cases, and this impairment is also associated with diminished amniotic fluid volume. These authors and previous authors [@b32-cln_73p1]-[@b35-cln_73p1] suggest that diminished renal flow in these fetuses may lead to a decreased glomerular count, which has also been observed in animal models [@b36-cln_73p1],[@b37-cln_73p1]. This reduction in glomerular number may not have a clinical impact in early life, but as the functional renal reserve is diminished, later renal injuries may cause more pronounced organ dysfunction.

Another possible mechanism of injury is fetal exposure to glucocorticoids, a growth inhibitory factor that may be a cause of structural and physiological alterations in blood pressure regulation [@b8-cln_73p1],[@b9-cln_73p1],[@b38-cln_73p1]. Glucocorticoids activate the renin-angiotensin system [@b12-cln_73p1],[@b39-cln_73p1] and change the hypothalamic-pituitary-adrenal axis [@b13-cln_73p1] as well as the vascular system, causing endothelial damage and increasing arterial tension [@b40-cln_73p1], which may impact renal function later in life. Additionally, considering that renal differentiation in mice can also be affected by a low-protein maternal diet [@b41-cln_73p1],[@b42-cln_73p1], the impact may occur even without centralization in exposed fetuses. Because adults born small for gestational age have a diminished renal reserve to manage any mechanism of renal damage in future life, any further risk factor, such as chronic hypertension and nephrotoxic drugs, may impact renal function [@b6-cln_73p1],[@b7-cln_73p1],[@b43-cln_73p1].

The finding that low birth weight is associated with renal damage in adulthood indicates the need for follow-up for individuals born below the 10^th^ percentile for weight [@b44-cln_73p1]. Earlier identification of individuals at a high risk for renal diseases through screening facilitates the diagnosis and management of further risk factors that may increase renal damage in the future, such as asymptomatic high blood pressure and diabetes [@b45-cln_73p1]. In addition, the prevention of microalbuminuria and end-stage renal disease by specific kidney protection measures, such as the use of angiotensin-converting antagonists in at-risk populations, may reduce disease progression and decrease mortality [@b45-cln_73p1]. These protective measures are included in guidelines that limit the high-risk population to individuals with diabetes mellitus, hypertension or a first-degree relative with diabetes, hypertension or kidney disease [@b46-cln_73p1],[@b47-cln_73p1]. But this new risk group, the low birth weight population, is not included in these primary prevention recommendations.

In contrast to previous meta-analyses [@b8-cln_73p1],[@b9-cln_73p1], we only included studies with sample populations older than 18 years of age and excluded extremely preterm births. This allowed us to reduce the number of patients with renal manifestations of undiagnosed congenital abnormalities and inherited diseases, which are frequent causes of end-stage renal disease in the first decades of life.

The initial objective of our group was to select only longitudinal prospective cohorts; however, the literature is limited, and no results from longitudinal prospective cohorts are available. Consequently, our study was limited to cross-sectional, case-control studies and retrospective cohorts. Another important difference of our study *versus* previous studies was the exclusion of high birth weight subjects among the controls when possible, which allowed better interpretation of the results because of the U-shaped relation between birth weight (low or high) and increased urinary albumin discharge due to diabetic end-stage renal disease [@b17-cln_73p1],[@b24-cln_73p1].

The selection of specific minorities to establish the study participants is an important source of bias in the literature and hinders the reproducibility of the results in the general population because low birth weight is suggested to be more common in some specific communities [@b17-cln_73p1]. Furthermore, end-stage renal disease is also related to other conditions, such as type 2 diabetes, and separating the role of the primary disease and the role of birth weight in its development is difficult. Despite all these possible sources of heterogeneity, the sensitivity analysis excluding each study individually led to non-significant changes in the results.

To study the effects of birth weight on the incidence of decreased renal function and kidney disease later in life, larger cohorts with longer follow-ups are recommended. Currently, considering the finding that renal function is impaired in adults born small for gestational age, societies must observe this population closely to determine a better follow-up strategy to reduce renal damage.

In conclusion, a positive correlation exists between low birth weight or small for gestational age and renal dysfunction in adulthood. This study provides the best evidence for this correlation based on the most homogeneous adult population available. However, well-designed prospective cohorts are needed to better understand the causality of this association and to identify possible interventions that will allow better recuperation of kidney glomerular capacity after intrauterine injury.
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###### 

Studies included in the meta-analysis.

  Author Year                                 Country         Design                                       Participants                                                                                                                           Age, years                                           Predictor                                                                                                               No. of Participants            Outcomes                                                                                                                         Frequency of Outcome/Value                                                                                 OR (95% CI)
  ------------------------------------------- --------------- -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------ -------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Nelson et al. ([@b26-cln_73p1]), 1998       United States   Prospective and retrospective cohort study   Pima Indians and closely related Tohono O\'odham Indians with type 2 diabetes                                                          34±8 Range: 20 to 61                                 LBW \<2500 g *vs.* Normal BW (between 2500 g and 4500 g)                                                                LBW: 16 Normal BW: 281         Microalbuminuria: ACR≥30 mg/g                                                                                                    LBW: 10 Normal BW: 114                                                                                     Microalbuminuria: 1.54 \[1.03, 2.31\]
  Hoy et al. ([@b7-cln_73p1]), 1999           Australia       Cross-sectional study                        Aborigines in the Australian Northern Territory                                                                                        27.1 Range: 20 to 38                                 LBW (\<2500 g) *vs.* Normal BW (≥250 0 g)                                                                               LBW: 111 Normal BW: 206        Albumin/ creatinine ratio (g/mol)                                                                                                LBW: 3.1 (2.2-4.3) Normal BW: 2.2 (1.7-2.8)                                                                ACR: 0.90 \[-0.12, 1.92\]
  Kistner et al. ([@b28-cln_73p1]), 2000      Sweden          Retrospective cohort study                   Women born full term in Stockholm                                                                                                      26±1.9                                               \(1\) BW \<2600 g and SGA (\<25^th^ percentile for gestational age) *vs.* (2) Normal BW for gestational age             (1): 18 (2): 17                Glomerular filtration rate (clearance of iohexol)                                                                                (1): 100±14 ml/min/1.73 m^2^ (2): 107±14 ml/min/1.73 m^2^                                                  GFR (ml/min/1.73 m^2^): -7.00 \[-16.28, 2.28\]
  Lackland ([@b20-cln_73p1]), 2000            United States   Case-control study                           Patients with chronic renal failure on dialysis from 1991 through 1996                                                                 34                                                   LBW (\<2500 g) *vs.* 2500 g ≤ BW \< 3999 g                                                                              LBW: 369 Normal BW: 2966       End-stage renal disease                                                                                                          LBW: 147 Normal BW: 959                                                                                    ESRD: 1.23 \[1.08, 1.41\]
  Vásárhelyi et al. ([@b29-cln_73p1]), 2000   Hungary         Prospective cohort study                     Healthy young Caucasian men                                                                                                            Range: 19 to 21                                      LBW (\<2500 g) *vs.* Normal BW (\>2500 g)                                                                               LBW: 49 Normal BW: 16          Glomerular filtration rate (Schwartz formula) Albumin/ creatinine ratio (g/mol)                                                  LBW: 127±22 ml/min Normal BW: 125±17 ml/min LBW: 0.91±2 g/mol Normal BW: 0.83±0.41 g/mol                   GFR (ml/min): 2.00 \[-8.36, 12.36\] ACR: 0.08 \[-0.58, 0.74\]
  Dyck et al. ([@b19-cln_73p1]), 2003         Canada          Case-control study                           Saskatchewan patients born after 1949 with ESRD diagnosed from 1981 through 1998                                                       \-                                                   LBW (≥2500 g) *vs.* Normal BW (between 2500 g and 4000 g)                                                               LBW: 47 Normal BW: 748         End-stage renal disease (dialysis or renal transplant)                                                                           LBW: 20 Normal BW: 235                                                                                     ESRD: 1.35 \[0.96, 1.92\]
  Gielen et al. ([@b27-cln_73p1]), 2005       Belgium         Cross-sectional study                        Monozygotic and dizygotic twins                                                                                                        25.6                                                 LBW (\<2500 g) *vs.* High BW (≥2500 g)                                                                                  LBW: 304 High BW: 349          Glomerular filtration rate (creatinine clearance corrected for body surface area)                                                LBW: 93±28 ml/min High BW: 98±27 ml/min LBW: 93±24 ml/min/1.73 m^2^ High BW: 94±22 ml/min/1.73 m^2^        GFR (ml/min): -5.00 \[-9.23, -0.77\] GFR (ml/min/1.73 m^2^): -1.00 \[-4.55, 2.55\]
  Al Salmi et al. ([@b22-cln_73p1]), 2006     Australia       Cross-sectional study                        Ausdiab study population                                                                                                               ≥25                                                  LBW (\<2500 g) *vs.* Normal BW (≥2500 g)                                                                                LBW: 42 Normal BW: 438         Glomerular filtration rate (serum creatinine and lean body mass)                                                                 LBW: 74.9 ml/min (69.3-80.5) Normal BW: 84.4 ml/min (82.7-86.1)                                            GFR (ml/min): -9.50 (-15.19; -3.81)
  Fan et al. ([@b18-cln_73p1]), 2006          United States   Cross-sectional study                        Caucasian and African American adults enrolled in the Medicaid program from 1993 to 1996 and diagnosed with diabetes or hypertension   Range: 18 to 50 Cases: 33.9±0.1 Controls: 37.6±0.6   LBW (\<2500 g) *vs.* Normal BW (between 2500 g and 3999 g)                                                              LBW: 860 Normal BW: 6037       End-stage renal disease                                                                                                          LBW: 27 Normal BW: 132                                                                                     ESRD: 1.44 \[0.96, 2.16\]
  Al Salmi et al. ([@b21-cln_73p1]), 2008     Australia       Case-control study                           Patients attending the Nephrology Department during the first quarter of 2004                                                          Cases: 63.1±14.4 Controls: 62.7±16.6                 LBW (\<2500 g) *vs.* Normal BW                                                                                          LBW: 20 Normal BW: 193         End-stage renal disease (GFR\>15 ml/min/1.73 m^2^ or on dialysis therapy)                                                        LBW: 13 Normal BW: 58                                                                                      ESRD: 2.16 \[1.47, 3.18\]
  Li et al. ([@b25-cln_73p1]), 2008           United States   Cross-sectional study                        Patients with diabetes or hypertension or with a first-degree relative affected, registered in KEEP                                    49.1±13.5 Range: 18 to 75                            LBW (\<2500 g) *vs.* Normal BW (between 2500 g and 3999 g)                                                              LBW: 1845 Normal BW: 9754      Microalbuminuria: ACR≥30 mg/g                                                                                                    LBW: 481 Normal BW: 1840                                                                                   Microalbuminuria: 1.38 \[1.27, 1.51\]
  Laganovic et al. ([@b24-cln_73p1]), 2012    Croatia         Cross-sectional study                        Healthy men                                                                                                                            Cases: 21±0.89 Controls: 21.5±1.02                   SGA (\<10^th^ percentile for gestational age according to the Croatian population) *vs.* AGA (\>2500 g and full term)   SGA: 95 AGA: 90                Glomerular filtration rate (Cockcroft-Gault equation) Microalbuminuria: 2.2\<ACR\<22 mg/mmol Albumin/ creatinine ratio (g/mol)   SGA: 118.99±21.99 ml/min AGA: 131.88±23.02 ml/min SGA: 12 AGA: 4 SGA: 1.29±3.4 g/mol AGA: 0.59±0.8 g/mol   GFR (ml/min): -12.89 \[-19.38, -6.40\] Microalbuminuria: 2.84 \[0.95, 8.49\] ACR: 0.70 \[-0.00, 1.40\]
  Ruggajo et al.([@b23-cln_73p1]), 2016       Norway          Retrospective cohort study                   Subjects registered in the Norwegian Renal Registry with ESRD or with a sibling who had ESRD or was SGA                                Range: 18 to 42                                      LBW (\< the sex-specific 10^th^ percentile) *vs*. Normal BW (\> 10th percentile)                                        LBW: 99170 Normal BW: 904964   End-stage renal disease (dialysis or kidney transplantation)                                                                     LBW: 45 Normal BW: 306                                                                                     ESRD: 1.34 \[0.98, 1.83\]

ACR, albumin/creatinine ratio; AGA, adequate for gestational age; BW, birth weight; ESRD, end-stage renal disease; GFR, glomerular filtration rate; LBW, low birth weight; SGA, small for gestational age.

###### 

Newcastle-Ottawa Quality Assessment Scale of the included studies (cohorts and case-controls).

  Study                                       Representativeness of the exposed cohort // Is the case definition adequate?   Selection of the non-exposed cohort // Representativeness of the cases   Ascertainment of exposure//Selection of controls   Demonstration that the outcome of interest was not present at the start of the study // Definition of controls   Comparability of (cohorts/cases and controls) based on the design or analysis   Assessment of (outcome/exposure)   Was the follow-up long enough for outcomes to occur? // Same method of ascertainment for cases and controls   Adequacy of the follow-up of cohorts // Non-response rate   Score
  ------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- -------
  Nelson et al. ([@b26-cln_73p1]), 1998       \*                                                                             \*                                                                       \*                                                 \*                                                                                                               \*                                                                              \*                                                                                                                                               \*                                                          **7**
  Kistner et al. ([@b28-cln_73p1]), 2000      \*                                                                             \*                                                                       \*                                                 \*                                                                                                               \*                                                                                                                                                                                                                               \*                                                          **6**
  Lackland et al. ([@b20-cln_73p1]) 2000      \*                                                                             \*                                                                       \*                                                                                                                                                                  \*\*                                                                            \*                                 \*                                                                                                                                                                        **7**
  Vásárhelyi et al. ([@b29-cln_73p1]), 2000   \*                                                                                                                                                      \*                                                 \*                                                                                                               \*                                                                              \*                                                                                                                                                                                                           **5**
  Dyck et al. ([@b19-cln_73p1]), 2003         \*                                                                             \*                                                                       \*                                                                                                                                                                  \*\*                                                                            \*                                 \*                                                                                                                                                                        **7**
  Al Salmi et al. ([@b22-cln_73p1]), 2008     \*                                                                             \*                                                                       \*                                                                                                                                                                  \*                                                                                                                                                                                                                                                                                           **4**
  Ruggajo et al. ([@b23-cln_73p1]), 2016      \*                                                                             \*                                                                       \*                                                                                                                                                                                                                                                                                     \*                                                                                                            \*                                                          **5**

###### 

Quality Assessment Tool for Cross-Sectional Studies included in the meta-analysis.

  Study                                     Research objective clearly stated?   Study population clearly defined?   Participation rate of eligible persons at least 50%?   All subjects recruited from similar populations?   Justification of the sample size?   Exposure measured prior to outcome?   Sufficient time frame to see an association between exposure and outcome?   Different levels of exposure measured?   Exposure measures clearly defined?   Exposure assessed more than once over time?   Outcome measures clearly defined?   Outcome assessors blinded to exposure status?   Loss to follow-up after baseline ≤20%?   Key potential confounders statistically adjusted for?   Score
  ----------------------------------------- ------------------------------------ ----------------------------------- ------------------------------------------------------ -------------------------------------------------- ----------------------------------- ------------------------------------- --------------------------------------------------------------------------- ---------------------------------------- ------------------------------------ --------------------------------------------- ----------------------------------- ----------------------------------------------- ---------------------------------------- ------------------------------------------------------- --------
  Hoy et al. ([@b7-cln_73p1]), 1999         **Y**                                **Y**                               **NR**                                                 **Y**                                              **N**                               **N**                                 **N**                                                                       **N**                                    **Y**                                **N**                                         **Y**                               **NR**                                          **N**                                    **N**                                                   **5**
  Gielen et al. ([@b27-cln_73p1]), 2005     **Y**                                **Y**                               **Y**                                                  **Y**                                              **N**                               **Y**                                 **N**                                                                       **N**                                    **Y**                                **N**                                         **Y**                               **NR**                                          **N**                                    **Y**                                                   **8**
  Al Salmi et al. ([@b22-cln_73p1]) 2006    **Y**                                **Y**                               **Y**                                                  **Y**                                              **N**                               **Y**                                 **CD**                                                                      **N**                                    **Y**                                **N**                                         **Y**                               **NR**                                          **N**                                    **Y**                                                   **8**
  Fan et al. ([@b18-cln_73p1]) 2006         **Y**                                **Y**                               **Y**                                                  **Y**                                              **N**                               **Y**                                 **N**                                                                       **N**                                    **Y**                                **N**                                         **Y**                               **NR**                                          **N**                                    **Y**                                                   **8**
  Li et al. ([@b25-cln_73p1]) 2008          **Y**                                **Y**                               **Y**                                                  **Y**                                              **N**                               **Y**                                 **Y**                                                                       **N**                                    **Y**                                **Y**                                         **Y**                               **NR**                                          **N**                                    **Y**                                                   **10**
  Laganovic et al. ([@b24-cln_73p1]) 2012   **Y**                                **N**                               **Y**                                                  **NR**                                             **N**                               **Y**                                 **N**                                                                       **N**                                    **Y**                                **N**                                         **Y**                               **NR**                                          **N**                                    **N**                                                   **5**

CD, cannot determine; N, no; NR, not reported; Y, yes.
